Roswell Park Comprehensive Cancer Center

Roswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.

A 10-week resistance program boosted cancer survivors’ strength, immune function, and gut microbiome.

New research highlights a promising investigational treatment using ziftomenib in a difficult-to-treat form of acute myeloid leukemia.

Roswell Park Comprehensive Cancer Center researchers will share key data at the 2026 ASCO Annual Meeting.

Researchers from Roswell Park led key studies presented at the 2026 AUA Annual Meeting.

Members of Roswell Park Comprehensive Cancer Center participated in the 2026 World Indigenous Cancer Conference.

Roswell Park Comprehensive Cancer Center launched a phase 2 trial evaluating SurVaxM plus temozolomide in progressing neuroendocrine tumors.

Research from Roswell Park Comprehensive Cancer outlines other potential uses for CDK inhibition in breast cancer management.

A preclinical study reveals that impaired functioning of 2 enzymes contributes to the development and progression of precancerous lesions in the pancreas.

Researchers at Roswell Park Comprehensive Cancer Center developed a two‑step therapeutic strategy designed to selectively eliminate tumors driven by TP53 mutations.

Roswell Park Comprehensive Cancer Center launched a trial of a new CAR T-cell therapy for AML that has relapsed or persisted despite earlier treatment.

Roswell Park Comprehensive Cancer Center researchers are investigating whether CAR T-cell therapy could target some of the most common autoimmune diseases.

A study shows that an AI pathology tool predicts whether a patient with extensive-stage small cell lung cancer will respond to platinum-based chemotherapy.

6-year Roswell Park study shows shorter, lower-dose approach works just as well as longer course of treatment

Study led by Roswell Park’s Dr. Brian Betts and Dr. Shernan Holtan highlighted in Blood Advances.

Andrew Hyland, PhD, of Roswell Park Comprehensive Cancer Center, received the 2026 John Slade Award from the Society for Research on Nicotine and Tobacco.

Roswell Park Comprehensive Cancer Center's Adult Multidisciplinary Neurofibromatosis Clinic was added to the NF Clinic Network.

Roswell Park Comprehensive Cancer Center highlighted key presentations from its researchers at TCT 2026.

The FDA-approved drug abatacept may improve treatment responses and prevent some immune AEs associated with CAR T-cell therapy.

Monitoring thymidine kinase activity levels may provide insights on response to CDK4/6 inhibitor therapy in breast cancer.

A research team at Roswell Park has identified an immune-suppressing metabolic checkpoint in the tumor microenvironment, and a way to overcome it.

The AACN's Beacon Award for Excellence has been awarded to Roswell Park Comprehensive Cancer Center's Intensive Care Unit.

Roswell Park Comprehensive Cancer Center welcomes Brian Higgins to its board of directors.

IL-36 gamma ‘armored’ CAR T cells boost effectiveness of therapies and help eradicate solid tumors according to researchers at Roswell Park.

A study led by Roswell Park Comprehensive Cancer Center reveals that a patient’s race and ethnicity can affect clinical outcomes for stem cell transplant.

Researchers at Roswell Park Comprehensive Care Center discover method of reducing acute graft-versus-host disease risk in blood cancers.

Roswell Park Comprehensive Cancer Center unveiled a comprehensive mobile cancer screening initiative for breast and prostate cancer.

Roswell Park Comprehensive Cancer Center is pleased to announce the recent accreditation of its rectal cancer program by the National Accreditation Program for Rectal Cancer.

Physical activity, from walking to strength training, helps boost recovery for patients after their stem cell transplants.

Roswell Park's National Cancer Institute-designated comprehensive cancer center will bring its expertise to the Capital Region.